Inflammation: canakinumab for the cryopyrin-associated periodic syndromes.
Savic
Sinisa
S
McDermott
Michael F
MF
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017326:Clinical Trials, Phase III as Topic; D056587:Cryopyrin-Associated Periodic Syndromes / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D053583:Interleukin-1beta; C541220:canakinumab